on Eckert & Ziegler Strahlen- Und Medizintechnik AG (isin : DE0005659700)
Eckert & Ziegler Expands with Approval of Illuccix® in Germany

Berlin-based Eckert & Ziegler celebrates the approval of Telix Pharmaceuticals' prostate cancer imaging agent, Illuccix®, in Germany. The firm is set to distribute Illuccix® through its subsidiary, Eckert & Ziegler Radiopharma GmbH. This strategic move enhances their nuclear medicine portfolio, particularly complementing GalliaPharm®, their high-quality generator for gallium-68, which is crucial for PET imaging in oncology.
CEO Dr. Harald Hasselmann emphasized leveraging their distribution network and market expertise to ensure accessible prostate cancer diagnostics. Telix's CEO, Raphaël Ortiz, welcomed the collaboration, anticipating strong access to gallium-based PSMA-PET imaging in Germany. This alliance underscores Eckert & Ziegler's dedication to advancing diagnostic solutions in oncology.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Eckert & Ziegler Strahlen- Und Medizintechnik AG news